Find Academic Supervisors

• Breast Cancer
• Chemotherapy
• Pharmacology
• +7 more

Della F. Makower, M.D. is an Oncology specialist at Montefiore Medical Center with a robust research portfolio focusing on breast cancer treatment, chemotherapy effects, and health disparities. With 49 publications and an h-index of 21, she has made significant contributions to understanding cancer treatment outcomes, particularly regarding social determinants of health and racial disparities in cancer care. Her research interests span multiple critical areas in oncology including: Breast Cancer (100% research focus) Chemotherapy (76% research focus) Recurrent Disease (61% research focus) Malignant Neoplasm (44% research focus) Endocrine Therapy (30% research focus) Hormone Receptor research (25% research focus) Dr. Makower's recent publications demonstrate a strong emphasis on health equity, with multiple studies examining racial disparities in cardiotoxicity, the impact of social determinants on cancer treatment outcomes, and specialized research on breast cancer in diverse patient populations. Her work frequently appears in high-impact journals including the Journal of the American Heart Association, Breast Cancer Research and Treatment, Cancer, and the Journal of Clinical Oncology. Notable research initiatives include: ECOG-ACRIN EA1131 trial comparing adjuvant platinum versus capecitabine for triple-negative breast cancer ECOG-ACRIN EAZ171 trial investigating germline predictors of taxane-induced neuropathy in Black women with breast cancer Studies examining the relationship between social determinants of health and anthracycline cardiotoxicity Research on the impact of the COVID-19 pandemic on breast cancer screening and diagnosis Her collaborative approach is evident in the multi-institutional nature of her research, with frequent collaborations across major cancer research networks. Dr. Makower's work has garnered significant attention, with multiple studies picked up by news outlets and discussed on social media platforms including X (Twitter) and Facebook.

• Radiation Oncology
• Brachytherapy
• Hodgkin Disease
• +7 more

Kenneth B. Roberts, MD , is a Professor of Therapeutic Radiology at Yale School of Medicine and a practicing academic physician specializing in pediatric cancers, lymphomas, leukemias, sarcomas, and colo-anal cancers. He serves as Chief of the Cardiac Brachytherapy, Lymphoma/Sarcoma Radiotherapy, and Pediatrics Radiotherapy Programs at Yale and is Associate Chief of Radiation Oncology at Yale-New Haven Hospital. Education : BS in Chemistry and Biology from Massachusetts Institute of Technology (1979) MD from Duke University (1984) Residency in Radiation Oncology at Duke University Medical Center (1992), Internal Medicine at Ohio State University Hospitals (1987) Fellowship in Hematology-Oncology at Duke (1989) MS in Legal Studies from Duke University School of Law (1994) Research Interests center on brachytherapy , combined modality therapy , and the long-term effects of radiation therapy (e.g., secondary malignancies). He investigates dose optimization in Hodgkin’s disease, radiation economics, and late toxicity in pediatric patients. Recent Publications focus on pediatric Hodgkin lymphoma , prognostic scoring in lymphomas, brachytherapy applications , and late cardiac toxicity in survivors. His work also addresses economic drivers in radiotherapy adoption and subsequent cancer risks . Scientific Awards Elected Fellow of ASTRO (2024) America’s Top Doctors in New York Metro Area (since 2005) America’s Top Doctors for Cancer (since 2006) 1998 Travel Award to European Society of Therapeutic Radiology and Oncology Clinical Trials include sub-investigator roles in studies on pediatric gliomas , stereotactic body radiotherapy for lung cancer, Inotuzumab Ozogamicin for leukemia, and germ cell tumors .

Zhenke WuView profile

Associate Professor

• Bayesian Statistics
• Precision Medicine
• Latent Variable Models
• +5 more

Zhenke Wu is an Associate Professor (with tenure) in the Department of Biostatistics at the University of Michigan School of Public Health. He holds affiliate appointments at the Michigan Institute for Data and AI in Society (MIDAS) and leads the Michigan Statistics for Individualized-healthcare Lab (MiSIL). His research bridges statistical methodology and public health applications, with particular focus on precision medicine. Educational background includes: PhD in Biostatistics from Johns Hopkins University (2014) BS in Mathematics from Fudan University (2009) Dr. Wu's methodological research focuses on: Structured Bayesian latent variable models for disease subtyping and clustering Causal inference methods for sequential interventions in mobile health studies Reinforcement learning frameworks for personalized health interventions Scalable computation for high-dimensional biomedical data His applied work spans infectious diseases, mental health, autoimmune disorders, and cancer through collaborations with multiple research consortia including the Intern Health Study and UZIMA-DS project in Africa. Recent publications demonstrate strong focus on Bayesian methods, causal inference, and reinforcement learning applications in digital health. Article themes include mobile health interventions, synthetic EHR development, fair machine learning algorithms, and novel approaches for longitudinal and survival data analysis. Methodological innovations consistently address challenges in precision medicine and individualized health decision-making. Dr. Wu leads several collaborative initiatives including the Precision Health Use Case for mental health treatment (PROMPT) and partners with the Rogel Cancer Center. He advises multiple PhD students and postdoctoral researchers in statistical methodology development and health applications.

• Gastrointestinal Oncology
• Clinical Trials
• Pharmacogenomics
• +6 more

Syma Iqbal, MD, is an Associate Professor of Clinical Medicine at the University of Southern California's Keck School of Medicine and Norris Comprehensive Cancer Center. She holds leadership roles as Medical Director for Inpatient Services at Norris Cancer Hospital, Medical Director of Ambulatory Services/Infusion Center, and Associate Cancer Physician in Chief. Dr. Iqbal chairs the Norris Clinical Investigations Committee and is a national thought leader in systemic therapy for esophageal and gastric cancers, including roles as co-Chair of the Southwest Oncology Group Esophago-Gastric Committee and Chair of the National Cancer Institute’s Esophago-Gastric Task Force. Dr. Iqbal graduated from the Keck School of Medicine of USC in 1995 and completed a Hematology and Oncology Fellowship in 2001. Her research focuses on clinical trials for gastrointestinal malignancies, pharmacogenomics in colorectal cancer, and molecular markers for treatment response and survival. Key publications highlight anti-HER2 therapies, PD-1 inhibitors, and genomic profiling in oncology. Her clinical trials span phase I-III studies in gastric, esophageal, colorectal, and pancreatic cancers, emphasizing drug combinations, resistance mechanisms, and biomarker-driven approaches. While no scientific awards are explicitly mentioned, her work has shaped national guidelines through leadership in cancer research consortia.

Ezequiel GoldschmidtView profile

Assistant Professor

• Neurosurgery
• Human Anatomy
• Developmental Biology
• +5 more

Ezequiel Goldschmidt, MD, PhD is an Assistant Professor in the Department of Neurological Surgery at the University of California, San Francisco (UCSF) . He is affiliated with the Brain Tumor Center and specializes in treating brain, skull base, and pituitary gland tumors using minimally invasive approaches . A proud member of the Latinx community, his research focuses on improving surgical techniques through human anatomy studies and exploring how developmental biology can enhance tumor growth understanding and brain recovery post-injury. Education: MD and PhD from Universidad de Buenos Aires Facultad de Medicina (2009) Residency in Neurosurgery at University of Pittsburgh Medical Center (2020) Postdoctoral Surgical Fellowship in Neuroplasticity at Karolinska Institute (Sweden) Research Interests: He investigates neurosurgical anatomy , endoscopic techniques , and brain tumor biology . His work includes determining risk factors for postoperative complications , application of indocyanine green (ICG) angiography , and genetic profiling of brain tumors . Clinical Trials: Dr. Goldschmidt leads trials on optic nerve stimulation to prevent visual deficits and ICG angiogram as a predictor of postoperative visual function. Scientific Awards: Fellowship in Skull Base Surgery at University of Pittsburgh Medical Center (2019) Fellowship in Neurosurgery Spine at University of Pittsburgh Medical Center (2015) Postdoctoral Surgical Fellowship in Neuroplasticity at Karolinska Institute Publications: His research spans minimally invasive neurosurgery , brain tumor classification , and intraoperative monitoring , with recent works on HPV-associated sinonasal cancer and immune checkpoint inhibition in meningiomas.

Jennifer De Los SantosView profile

Professor

• Breast Cancer
• Radiation Therapy
• Head and Neck Cancers
• +5 more

Jennifer De Los Santos, MD is a Professor of Radiation Oncology at Washington University School of Medicine in St. Louis. She serves in the Department of Radiation Oncology and is part of the Siteman Cancer Center. Dr. De Los Santos is a nationally recognized expert in breast cancer although her current clinical and research focus centers on cancers of the head and neck. She has held leadership positions including Chairman of Radiation Oncology and Cancer Center Director at Grandview Cancer Center in Birmingham, Alabama, and has led national studies in breast cancer through the TBCRC and NRG oncology groups. Dr. De Los Santos' educational background includes a BS in Psychology from Emory University (1991), an MD from the University of Florida (1995), and completed her residency in Radiation Oncology at MD Anderson Cancer Center (2001). Her research interests span breast cancer treatment, radiation therapy techniques, and head and neck cancers, with particular focus on developing paradigm-shifting treatment approaches and translational work to define populations who may successfully proceed with these approaches. Her publication record demonstrates consistent productivity with 68 research outputs and 2973 citations. Recent work shows a strong focus on breast cancer staging systems, pathological response prediction, and innovative treatment approaches including novel combinations of targeted therapies with radiation. Her research often involves large national clinical trials through NRG Oncology and other cooperative groups. Dr. De Los Santos has served in leadership roles at the Translational Breast Cancer Research Consortium (TBCRC), the University of Alabama at Birmingham, and has been involved in numerous national clinical trials that have shaped breast cancer treatment guidelines. Her work bridges clinical practice and research, with emphasis on improving outcomes for cancer patients through innovative treatment approaches and better understanding of treatment response predictors.

• Acute Lymphoblastic Leukemia
• Pediatric Brain Tumors
• Genetic Heterogeneity
• +5 more

Stephen E. Sallan, MD , is a Professor of Pediatrics at Harvard Medical School and a Physician at Dana-Farber Cancer Institute and Children's Hospital . His career spans over five decades in pediatric hematology/oncology , with a focus on acute lymphoblastic leukemia (ALL) and pediatric brain tumors . Education : MD, Wayne State University School of Medicine (1967) Residencies : Boston Floating Hospital (1968), Children's Hospital of Philadelphia (1969), Hospital for Sick Children, London (1970) Fellowship : Pediatric Oncology, Children's Hospital/DFCI (1972) Leadership Roles : Chief of Staff (1995), Chairman of Medical Staff Executive Committee (1995), Chief of Staff Emeritus (2012) Dr. Sallan's research integrates genetic heterogeneity , disease recurrence , and drug resistance in ALL, with efforts to develop targeted therapies like tumor vaccines and antiangiogenesis agents. His work addresses long-term treatment toxicities (cardiac, skeletal, neurocognitive), particularly in survivors of childhood cancers. His 15 most recent publications (2024–2018) demonstrate ongoing engagement with pharmacogenomics, thrombosis risk models, dietary interventions, and molecular markers in brain tumors. Key subfields include TRK-C in medulloblastoma , asparaginase complications , and DFCI ALL Consortium Protocols . Scientific Awards : Distinguished Alumni Award, Wayne State University School of Medicine (1997) James Carreras Prize for International Pediatrician of the Year (1987) As a leader in pediatric leukemia research , Dr. Sallan has shaped treatment protocols that minimize late effects while improving survival. He collaborates with multidisciplinary teams in neuro-oncology and pharmacogenomics, maintaining active roles in clinical trials and laboratory investigations.

Eleni Greenwood JaswaView profile

Assistant Professor

• Polycystic Ovary Syndrome (PCOS)
• Mental Health and Wellness in Reproductive Disorders
• Fertility Biomarkers
• +6 more

Dr. Eleni Greenwood Jaswa serves as an Assistant Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California San Francisco (UCSF), where she practices as a Reproductive Endocrinologist at the UCSF Center for Reproductive Health. Her clinical expertise spans infertility treatment, fertility preservation (including egg/embryo freezing), and management of reproductive endocrine disorders such as PCOS, menopause, recurrent miscarriages, and menstrual abnormalities. Education MS in Biological Sciences, Stanford University (2007) MD, Weill Cornell Medicine (2012) Residency in Obstetrics and Gynecology, UCSF (2016) Fellowship in Reproductive Endocrinology and Infertility, UCSF (2019) Research Focus : Dr. Jaswa's work centers on PCOS pathophysiology with emphasis on mental health comorbidities, cardiometabolic interactions, and fertility biomarkers. She pioneers research on patient experiences with egg freezing and develops dynamic methodologies to address persistent challenges in reproductive medicine, particularly in unexplained infertility and preimplantation genetic testing. Publication Analysis : Her 15 most recent publications (2018-2020) reveal three dominant research streams: PCOS (60% of output, focusing on mental health-metabolic interplay), preimplantation genetic testing (25%, emphasizing platform reliability and ethnic disparities), and fertility preservation (15%, analyzing patient decision-making and outcomes). Notably, 40% of her work addresses health equity through multiethnic cohort studies. Scientific Recognition John Metcalf Polk Prize (Weill Cornell's highest scholastic honor) Alpha Omega Alpha Honor Medical Society induction UCSF Excellence in Teaching Award Clinical & Research Integration : Dr. Jaswa leads multidisciplinary collaborations between UCSF's reproductive laboratory, psychological support services, and genetic counseling teams. Her current NIH-funded projects investigate PCOS management through integrated mental-physical health interventions and develop predictive models for fertility preservation success. Women's Health Advocacy : Motivated by her mother's breast cancer death at age 35, she co-develops community programs with her sister (a UCSF breast radiologist) to advance early detection and holistic women's healthcare through the UCSF Women's Health Initiative.

• Radiotherapy
• Non-melanoma Skin Cancer
• Merkel Cell Carcinoma
• +3 more

Clinical Professor Michael Veness is a full-time Radiation Oncology specialist at Westmead Hospital, Sydney, with appointments at the Sydney Medical School, University of Sydney since 1998. His clinical research focuses on radiotherapy for non-melanoma skin cancer , particularly Merkel cell carcinoma and high-risk cutaneous squamous cell carcinomas . Veness maintains a large prospective database for advanced skin cancers and has published over 160 peer-reviewed works. Education: Master of Clinical Epidemiology, MD from University of NSW and University of Sydney Research Interests include: Clinical benefits of radiotherapy in skin cancer Definitive and adjuvant radiation protocols Merkel cell carcinoma epidemiology High-risk cutaneous malignancies Prognostic staging systems Article Trends show sustained focus on radiotherapy applications for non-melanoma skin cancers , with emphasis on Merkel cell carcinoma and cutaneous squamous cell carcinomas . Recent works analyze metastatic patterns, immunotherapy integration, and staging system improvements. Clinical Approaches combine radiation therapy with surgical interventions, including sentinel lymph node biopsy protocols. His collaborations span multiple institutions, with significant contributions to head and neck cancer clinical guidelines.

• Otorhinolaryngology
• Head and Neck Surgery
• Otolaryngology

Yusuf AYDIN serves as a full-time Lecturer in the Department of Surgical Medical Sciences at Kastamonu University's Faculty of Medicine since 2025. A specialist in Ear, Nose and Throat Diseases, he completed medical training at Karadeniz Technical University and ENT specialization at Istanbul Gaziosmanpaşa Taksim Training Hospital. His clinical-academic work bridges surgical innovation with patient care in head and neck pathologies. Education: Doctorate in Ear, Nose and Throat Diseases, Istanbul Gaziosmanpaşa Taksim Training and Research Hospital (2011-2016) Bachelor of Medicine, Karadeniz Technical University, Faculty of Medicine (2005-2011) Research Focus: Dr. AYDIN specializes in Otorhinolaryngology with emphasis on Head and Neck Surgery . His work explores rare tumor pathologies (e.g., schwannomas in adolescents), surgical techniques for lacrimal system disorders, sudden sensorineural hearing loss, and metastasis predictors in head/neck cancers. Current investigations prioritize endonasal approaches and pediatric ENT case complexities. Publication Trends: Recent output (2024-2025) features clinical case reports on tongue schwannoma and comparative studies of endonasal dacryocystorhinostomy. His book chapter on sudden hearing loss addresses emergency protocols, while 2018 research analyzed tumor-metastasis correlations. Publications consistently target surgical outcome optimization across ENT subspecialties. Professional Recognition: Member of Turkish Ear Nose Throat Head and Neck Surgery Association (2025-present) 7 documented research collaborations including Fatma Atalay (2025) and Ceki Paltura (2018) No scientific awards, grants, or student supervision records exist. His research infrastructure shows no dedicated laboratory facilities.

Kevin A. WalterView profile

Professor

• Neurosurgery
• Oncology
• Neuro-oncology
• +6 more

Dr. Kevin A. Walter is Chief of Neurosurgery at UR Medicine's Highland Hospital and a Professor of Neurosurgery and Oncology at the University of Rochester Medical Center. He holds joint appointments in the Department of Orthopaedics (SMD) and the Cancer Center. Dr. Walter earned his MD at Johns Hopkins University School of Medicine, completed neurosurgical residency and a neuro-oncology fellowship at Johns Hopkins, and served as Director of Adult Neuro-oncology at the University of Pittsburgh before joining Rochester in 2007. Dr. Walter's research focuses on experimental therapeutics for brain and spinal tumors, with a particular emphasis on improving patient survival and quality of life through clinical trials and laboratory investigations into tumor biology. His work spans glioblastoma, radiosurgery, and complex spinal interventions. His recent publications highlight advancements in dendritic cell vaccination for glioblastoma (2023), tumor treating fields (2020), and recurrence patterns post-chemoradiation. Earlier studies (2010-2007) explored vascular gene expression, spinal cord gliomas, and radiosurgery efficacy. NREF Young Investigator Award (2003) Blue Ribbon Presentation (2001) Hunterian Resident Neurosurgical Research Award (2001) Outstanding Presentation (2000) Hunterian Medical Student Neurosurgical Research Award (1995) Alpha Omega Alpha (1995) Dr. Walter conducts clinical research evaluating experimental therapies for brain and spinal cancers, including trials on dendritic cell vaccines and tumor treating fields. He also leads a research laboratory at the University of Rochester focused on novel tumor targets and drug delivery systems like biodegradable polymers.

Abel TorresView profile

Associate Professor

• Dermatology
• Public Health
• Medical Ethics
• +5 more

Abel Torres, MD, JD serves as Associate Professor at Loma Linda University School of Public Health with concurrent adjunct appointments in Dermatology and Basic Sciences at the School of Medicine. His academic profile bridges clinical dermatology, public health policy, and medical legal frameworks, reflecting his dual medical and legal credentials. His educational background includes a BS from New York University (1977), MD (1979), and JD from Loyola Marymount University (1991). Clinical training encompasses Internal Medicine Internship and Residency at Loma Linda University Medical Center (1979-1982), Dermatology Residency at New York University Medical Center (1982-1985), and specialized fellowships in Advanced Dermatologic Surgery/Mohs Surgery at UCSF (1985-1986) and Wound Healing at NYU Medical Center. Medical Degree: 1979 Juris Doctor: 1991 BS: 1977 Torres' research spans dermatologic surgery, skin cancer management, medical ethics, and medicolegal issues. His work examines ethical dilemmas in cosmetic procedures, teledermatology implementation, diversity in dermatology, and regulatory compliance. Recent publications analyze title protection laws for physicians, adolescent cosmetic procedures, and rural dermatology workforce development, demonstrating his unique intersection of clinical practice and legal scholarship. Analysis of his 60+ publications reveals consistent focus on risk management in dermatologic procedures, evolving standards in Mohs surgery, and ethical frameworks for emerging technologies. His scholarship increasingly addresses healthcare disparities and diversity initiatives alongside traditional clinical topics. Torres contributes to dermatology residency and fellowship programs at Loma Linda, which include ACGME-accredited Procedural Dermatology training. The department offers specialized clinical services in General Adult Dermatology, Pediatric Dermatology, Psoriasis, Phototherapy, and Procedural Dermatology including Mohs surgery and cosmetic procedures. His academic service includes participation in consensus guideline development, as evidenced by co-authorship on ASDS cosmetic dermatologic surgery fellowship milestones and isotretinoin procedural intervention recommendations. His work on cultural competence for 21st century dermatologists reflects commitment to inclusive medical practice.

J. Fernando QuevedoView profile

Professor

• Genitourinary cancers
• Prostate cancer
• Bladder cancer
• +4 more

Dr. J. Fernando Quevedo is a faculty physician at Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, specializing in medical oncology with expertise in genitourinary malignancies. His clinical and research focus encompasses prostate, bladder, kidney, and testicular cancers, particularly biomarker development and therapeutic optimization. Education: 1994 Fellow - Palliative Care/Hematology-Oncology, Cleveland Clinic 1993 Fellow - Hematology/Oncology, Mayo Clinic Rochester 1985 MD - Catholic University School of Medicine, Guayaquil Research Focus: Dr. Quevedo investigates clinical and translational aspects of genitourinary cancers, with emphasis on radiation therapy protocols, serum biomarkers (chromogranin A, miRNAs), genetic predictors of treatment response, and therapeutic side-effect management. His work frequently involves multi-institutional collaborations. Publications: His 28+ publications demonstrate consistent focus on prostate cancer (70% of recent works) and renal cell carcinoma (25%), with thematic emphasis on treatment resistance, metastasis biology, and precision oncology approaches. Recent articles show growing interest in radionuclide therapies and tyrosine-kinase inhibitor toxicities. Awards: 2005 Teacher of The Year - Mayo Fellows Association Professional Engagement: Active member of ASCO, ECOG, and RTOG; organizer of international oncology meetings including Best of ASCO and SOLCA conferences.

• Neurosurgery
• Spine Surgery
• Brain Tumors
• +3 more

Sasha Gulati is a Professor at the Norwegian University of Science and Technology and a Consultant Neurosurgeon at St. Olavs Hospital, specializing in Neurosurgery within the Department of Neuromedicine and Movement Science. Their work bridges clinical practice with extensive research in spinal and brain disorders. Research interests span spinal pathologies (degenerative cervical/lumbar diseases, radiculopathy, recurrent disc herniation), brain tumors (gliomas, meningiomas), cerebrovascular conditions (aneurysms, subarachnoid hemorrhage), and functional outcomes post-neurosurgery. Key themes include occupational rehabilitation , registry-based comparative studies , and pharmacoepidemiology in postoperative care. Recent publications (2020-2025) focus on spinal cord stimulation for chronic pain, shunt surgery complications , return-to-work outcomes after neurosurgical interventions, and demographic risk factors in aneurysm and glioma management. Collaborative work spans Scandinavia, utilizing national registries for large-scale clinical insights.

Ari JamshidiView profile

Lecturer

• Science Education
• Curriculum Development
• Teacher Professional Development
• +3 more

Ari Jamshidi serves as a Lecturer at the University of California, Berkeley's College of Engineering. His primary affiliations include: CalTeach program: Coordinating the Summer Research Institute (a Research Experience for Teachers initiative) that connects undergraduate STEM students and in-service teachers with engineering research Stanford Center for Assessment, Learning, and Equity (SCALE): Developing NGSS-aligned science curriculum and teacher professional development OpenSciEd initiative: Creating equitable storylines for middle school science education nationwide His professional expertise bridges two distinct domains: Science Education: Specializing in NGSS implementation, project-based curriculum design, performance-based assessments, and teacher training through partnerships like San Francisco Unified School District Healthcare Data Science: Focusing on genomic assay validation (21-gene Recurrence Score, DCIS Score), breast cancer recurrence modeling, and healthcare decision support systems Publication analysis (2015-2021) reveals concentrated work in breast cancer genomics, particularly clinical validation of genomic predictors for recurrence risk and treatment response. Recent work shifts toward healthcare data infrastructure, with his 2021 publication introducing a novel analytics framework for medical decision-making. At Berkeley, Jamshidi leads the CalTeach Summer Research Institute that translates engineering research into K-12 classroom experiences. His Stanford SCALE collaboration extends this translational approach to national science education standards through OpenSciEd's teacher resources.